Introduction
Delay of growth and occasional complete regressions of an established allogeneic tumor by the injection of antisera and lymphoid cells have been reported (7, 8, 15, 19, 23, 24) , but in general these methods were unsuccessful with syngeneic tumors which did not elicit a homograft reaction (for a review see Ref. 20) . A notable exception which forms the starting point of the present investigation was the finding by Gorer and Amos (13) that the growth of the E.L.4 leukemia in its strain of origin could be prevented by injecting antisera prepared in a different strain of mouse. The serum was most effective if given prophylactically, had some effect if injected 1 day after the E.L.4 cells were trans planted, but was ineffective if given 2 days later. A similar effect was produced by Levi (16) with heterologous sera from rabbits 1This investigation has been supported by grants to the Chester Beatty Research Institute (Institute of Cancer Research: Royal Cancer Hospital) from the Medical Research Council and the British Empire Cancer Campaign and also by Research Grant CA-03188-08from the National Cancer Institute, USPHS.
Received for publication August 9, 1965 ; revised January 18, 1966 . made tolerant to mice and then immunized with murine leukemia cells. Klein et al. (14) found that mixing sarcoma cells in vitro with lymphocytes from allogeneic immunized animals was much more effective than incubation in vitro with antiserum in pre venting these tumors from growing on subsequent inoculation into a syngeneic host. This led us to explore the use of lympho cytes for treatment of primary sarcomas and syngeneic leukemias. Delorme and Alexander (9) obtained regressions and occasionally complete cures of primary sarcoma in the rat by i.v. injection of immune thoracic duct lymphocytes. This procedure was effective both when the lymphocytes were donated by syngeneic animalsâ€"and therefore only directed against the tumor-specific antigens, which were shown to be presentâ€"as well as by allo geneic donors when transplantation antigens are also involved. Autologous spleen cells obtained from the autochthonous host bearing the primary tumor also prevented the growth of sarcoma cells on transplantation into syngeneic recipients (18) .
In this paper results which have been reported preliminarily (4) will be described on the treatment of DBA/2 mice bearing a chemically induced leukemia, L5178Y originating in this strain, with spleen cells and sera from allogeneic mice immunized with these cells. This leukemia (10) was chosen because it grows from an inoculum of 1 cell both in vivo and in vitro. The growth in culture makes it possible to study directly the action of lympho cytes and sera on cell multiplication. In vitro investigations were not therefore limited to morphologic tests, which may not reveal damage that results primarily in interference with cell division without causing lysis. From a cancer point of view the relevant criterion for cytotoxicity is loss of growth ability and not "physio logic" death as seen by the breakdown of the plasma membrane.
The major disadvantage in using this leukemia is that the cell line has been transplanted for many years and there is a possi bility that there is a substrain variation between the mouse of origin and the DBA/2 mice used in this investigation. We can therefore not be certain whether the additional transplantation type antigen present in the tumor and absent from normal DBA/2 tissue, which the current studies have revealed and which are responsible for the effects reported here, is a tumor-specific antigen associated with chemical carcinogenesis or a transplanta tion antigen due to substrain variation. If it is the latter it is weak, since the L5178Y cells used will grow from 1 cell in DBA/2 mice and never regress, while in other strains progressive tumor growth is only obtained if the initial inoculum contains many cells.
Materials and Methods
L5178Y LYMPHOMA. The lymph orna used in this study was obtained from Dr. Fischer's laboratory at Yale in 1961 and had originally been induced by methylcholanthrene in adult DBA/2 mice. The tumor has since been serially passaged in our own inbred colony of DBA/2 and has been shown to grow from the i.p. inoculation of 1 cell. The lymphoma grows at 1st as an ascites in the peritoneal cavity. Microscopic observation indicates that the infiltration of tumor cells into various organs is negligible in the 1st 5 days after transplantation although aggregates of tumor cells are found in the mesentery prior to death. Failure to obtain a tumor by transplanting spleen, liver, and marrow from animals that had received an injection of L5178Y cells 4 days earlier confirms that the tumor is initially localized to the peritoneal cavity. Subcutaneous inoculation of tumor cell suspension gave rise to a solid tumor.
The rate of cell proliferation indicated that the doubling time in vivo was initially 11-12 hr. After the i.p. injection of 1000 L5178Y cells, used as our standard inoculum in DBA/2 mice, the average killing time was 26-27 days. The ascitic fluid which occasionally developed after the i.p. injection of 3-7 X IO6 L5178Y cells into C57BL and CBA mice, had always regressed completely 21 days after inoculation.
MICE.Mice of strains DBA/2, CBA, and C57BL were obtained from our own colonies, maintained by brother and sister matings. All mice received tail vaccination against ectromelia between 30 and 35 days of age. Animals were used experimentally between 2 and 4 months of age.
SPLEENANDSERUMPREPARATIONS. After cutting alongside the ridge of the splenic capsule the cells were gently forced out with fine sterile forceps into Tissue Culture Medium 199. Serum was obtained by heart puncture; it was not heated to retain comple ment activity and was used within 2 or 3 hr.
IMMUNIZATION PROCEDURE. Tumor immunization: Spleen cells and serum were taken from animals immunized in 1 of 2 ways. Singly immunized mice were used 21-23 days after inocu lation with 3-7 X IO6 L5178Y cells. Hyperimmunized mice given 3 inoculations at 21-to 24-day intervals were used 7-10 days after the last immunization. The cell numbers for each individual immunization are shown in the tables.
Spleen immunization: The cell numbers for each individual immunization given at 10-day intervals are shown in the table. Spleens were removed 7-10 days after the last immunization.
X-IRRADIATIONOF L5178Y OR DBA/2 SPLEEN CELLS.All irradiations were given with a 250-kv Marconi machine with no filter. The cells at the dilution required for inoculation, suspended in Medium 199, were irradiated in air in a test tube 10 cm from the source at a dose rate of 750 r/min, giving a total of 3000 r.
FREEZING ANDTHAWING. The immune spleen cells in Medium 199 were alternately exposed to a mixture of solid CÃoe2and alcohol, until the cell suspension was frozen, and to water at 37Â°C, until the suspension had thawed. Each of these freezing and thawing operations was repeated 6 times.
SERUMABSORPTION. Sera were absorbed twice with equal volumes of washed perfused liver or L5178Y cells for 30 min at 37Â°C.
TISSUECULTURE. L5178Y cells were grown in vitro in a special medium devised by Fischer (10) Reproducible results are only obtained if no serum is present at the stage of initial interaction between the tumor and spleen cells. Subsequent to the incubation at high cell concentration the cells were spun down and were resuspended in Fischer medium containing horse serum to give a final concentration of about 5 X 10" lymphoma cells +1.5-2.5 X IO7spleen cells/ml. After 24 hr the suspensions were further diluted in order to avoid ex haustion of the medium and change in the pH. The surviving cells were counted in a hemocytometer daily for 3 or 4 days. The tumor cells can, with experience, be readily distinguished from spleen cells on the basis of their size and morphology. After 24 hr the microscopic appearance of actively growing lymphoma cells and of the small proportion of large cells derived from the spleen shows very characteristic differences.
Results
TREATMENT WITHALLOGENEicSPLEENCELLS.Earlier experi ments (14, 18, 21) had shown that the addition of immune spleen cells to tumor cells prior to inoculation prevented the growth of the latter in vivo, but to be effective the ratio of spleen to tumor cells had to be of the order of 200:1. These observations indicated that treatment of a tumor in vivo with spleen cells was only likely to be successful if the number of tumor cells that need to be eradicated was relatively small. For this reason, the standard test procedure was to inject 1000 L5178Y cells i.p. and to treat the animals with immune cells 2 days later, by which time the ascites tumor had grown to approximately 20,000 cells. The viability of every suspension of L5178Y cells used was tested by injecting 1000 colls i.p. into 5 DBA/2 mice to give 100% tumor incidence. Table 1 shows that spleen cells from normal allogeneic donors are almost without effect on the growth of the lymphoma, and no instance has been encountered in which they produce a graft versus host reaction syndrome. Immunization with the tumor, however, renders the spleen cells effective. When given at a ratio of 400:1 (i.e., 8 X IO6spleen cells injected into animals inoculated 2 days previously with 1000 lymphoma cells) the elimination of tumorâ€"defined as absence of any size of tumor at 35 daysâ€"is close to 100%. Successfully treated animals were kept for a number of months, and not a single case occurred in which an animal without a palpable ascites at Day 35 developed a tumor later. In a normal animal 1 viable lymphoma cell is sufficient to produce a tumor lethal within 35 days, but this does not mean that the injected immune lymphocytes were directly responsible for the destruction of every tumor cell since the possibility exists that an immune response was induced in the autochthonous host which may have contributed to the complete elimination of every tumor cell. Table 2 shows that it is possible to obtain some beneficial effect in animals that contained approximately 2 X IO5tumor cells at the time of treatment, but complete tumor regressions were infrequent probably because the optimum ratio of immune spleen cells was not administered.
The genetic constitution of the donors does not appear to be critical, and effective tumor elimination has been obtained using spleen cells not only from CBA mice immunized with L5178Y cells, but also with cells from C57BL which, however, gave less consistent results. Hyperimmunization appears to be slightly more effective than a single immunization. Immunization with lymphoma by the s.c. route seems to be somewhat less effective (see Table 1 ) than by i.p. injection, and the latter procedure has therefore been used throughout. If the L5178Y cells are rendered incapable of division by irradiation with 3000 r of X-rays they are much less effective than live cells after a single immunization. Disruption of the L5178Y cells by freezing and thawing greatly reduces, but does not entirely abolish, the capacity to produce antitumor spleen cells even after hyperimmunization (see Table 1 ), and in this respect these lymphoma cells resemble other tumor cells which have been shown to lose their antigenicity when disrupted (21) . Freezing and thawing of the spleen cells from immunized mice destroy their ability to act against the tumor cells, and antibody activity has not been dissociated from the cells.
The spleen cells are most effective if injected i.p. into an ascites tumor possibly because cell-to-cell contact is facilitated under these conditions. Some activity is retained, however (see Table 2 ), if the routes of administration require systemic transport of the spleen cells. Some inhibition of tumor growth is also seen if a "solid" tumor, growing subcutaneously, is treated with spleen cells given i.p. ; the reverse procedure of treating the ascites tumor with spleen cells given s.c. delays the growth of the ascites tumor, but does not eliminate it completely.
7s the reaction directed against the normal transplantation antigen or the tumor-specific antigens? Immunization with lymphoma cells must lead to the formation of antibodies (free and cell bound) which are directed both against the histocompatibility barriers between DBA/2 mice and the mice used as donors and against the antigens specific to L5178Y cells. The failure to produce any indications of a graft versus host reaction suggests that the injected immune spleen cells do not destroy a large fraction of the normal cells in the gut or retiuloendothelial system of the DBA/2 mice, and this makes it unlikely that the anti-DBA/2 component (e.g., lymphocytes directed against the H2 antigens) are responsible for the extensive destruction of the tumor cells; this is particularly evident where the spleen cells have been injected at a site away from the tumor. More compellingevidence for the hypothesis that the in vivo antitumor effect of allogeneic spleen cells is produced by lymphoid cells directed selectively against the specific antigens is provided by the following observations:
1. Hyperimmunization of CBA and C57BL mice with spleen cells from DBA/2 mice does not produce cells which hold up the growth of the tumor (see Table 1 ). Immunization with normal DBA/2 tissue will lead to the production of lymphocytes directed against the normal transplantation antigens, and this activity can be detected by in vitro tests (see below) ; yet such cells are quite ineffective against the tumor in vivo. It might be argued that the difference between immunization with tumor and with normal cells is purely quantitative because L5178Y cells are more antigenie since they multiply for a time in the allogeneic hosts. This difference should be compensated by the fact that a single im munization with L5178Y is comparable to hyperimmunization by spleen cells. Moreover, a single immunization with radiationtreated lymphoma cells which cannot divide further after injec tion causes the formation of active spleen cells (see Table 1 ). 2. If the spleen cells directed against the normal histocom patibility antigens played a part in the antitumor action then they should be rendered inactive by being mixed in vitro for 30 min with an excess of normal DBA/2 spleen cells with which they interact by a homograft reaction. Table 3 shows that this type of absorption procedure does not eliminate the antitumor action. Â°Cells (IO7) irradiated with 3000 r in vitro were injected i.p. (5)] and lose antigenicity following irradiation. Sarcoma cells after 10,000 r of Xrays remain "physiologically" alive and retain their antigenicity, but a dose of this magnitude is not tolerated by the L5178Y lymphoma. A dose of 3000 r, under aerobic conditions, prevents the lymphoma cells from producing tumors but induces an im mune state so that the animals are able to reject up to IO4 tumor cells (Table 4) . It is not clear whether this is the maximum degree of resistence against this tumor which DBA/2 mice are capable of developing, or whether the relatively low degree of resistance is due to low antigenicity of irradiated cells. Spleen cells taken from DBA/2 mice rendered immune against the lymphoma can be used to treat the tumor in vivo (see Table 5 ) though the syngeneic immune cells are less effective than allogeneic immune spleen cells.
TREATMENT WITH HETEROLOGOUS SPLEEN CELLS. Albino rats of
the Chester Beatty Research Institute stock were hyperimmunized by i.p. injection with 10s lymphoma cells. The spleen cells from the rat were ineffective for treatment of DBA/2 mice even when injected at a ratio of 2000 spleen cells for every lym phoma cell. The spleen cells from immunized rats showed some antitumor activity in vitro (see below) and their failure in vivo may be due to rapid destruction in the mouse by a nonspecific mechanism.
TREATMENTWITH ANTISERUM.Injection of sera from CBA or C57BL mice that had received a single immunization with L-5178Y cells produced no observable change (i.e., neither retarda tion nor enhancement) in the growth of a tumor from IO3 lym phoma cells inoculated 2 days before giving the serum. The serum from hyperimmunized animals was, however, effective under the same conditions (Table 6 ). The reason why Gorer and Amos (13), using essentially the same procedure, failed to eradicate E.L.4 leukemia in vivo and only observed retardation of growth, is probably a quantitative one in that these authors treated animals which had received an inoculum of more than 5 X IO3 cells 1 or 2 days earlier and the size of the tumor may have been too great to respond to immunologie methods. Serum from hyperimmunized mice is less efficient than are spleen cells from single or hy perimmunized donors respectively when expressed as the total anti-LSI 78Y cytotoxic capacity per immunized mouse.
The serum from rats that were immunized with lymphoma was extremely toxic, as might be expected from a heterologous antiserum. After absorption on liver from DBA/2 mice the serum became nontoxic and was very effective in treating the leukemia in DBA/2 mice (see Table 6 ). The usefulness of suitably absorbed heterologous antitumor serum may be confined to the treatment of tumor cells of lymphoid origin (unpublished observation) since it is ineffective (indeed produces enhancement) when given to rats with fibrosarcoma although these tumors respond to treat ment with lymphocytes (9).
INHIBITION OF TUMOR GROWTH BY MIXING LYMPHOMA CELLS
WITH SPLEEN CELLSIN VITRO. Several investigations (14, 18, 21) have shown that the addition of immune lymphocytes to tumor cells interferes with their growth on injection into syngeneic ani mals. The same phenomenon is seen with the L5178Y cells ( Table  7) . To achieve loss of ability to grow in vivo these cells must be incubated with the spleen cells at high cell concentrations (i.e., IO6 L5178Y cells/ml) which are diluted prior to injection into mice. Under these "semi in vitro" conditions the average number of spleen cells needed to prevent the lymphoma cells from grow ing is similar to that observed in vivo (i.e., in the range of 200-400 spleen cells/lymphoma cell). It is noteworthy that when the cells are mixed in vitro, spleen cells directed only against DBA/2 transplantation antigens (i.e., from animals immunized with DBA/2 spleen cells) are effective while in vivo they are without activity. This provides further evidence for the view that the in vivo antitumor activity of the spleen cells depends chiefly on the activity directed against the specific antigen of the tumor.
EFFECT OF SPLEEN CELLS ON GROWTH OF LYMPHOMA CELLS IN
CULTURE. Lymphocytes from suitably immunized allogeneic animals have been shown to adhere to sarcoma cells in tissue culture and to interfere with their growth (22, 25, 26 ). An effect of spleen cells could be very clearly demonstrated with L5178Y cells which grow in culture with a doubling time of 14-18 hr as isolated and detached cells in the special medium devised by Fischer (10) . Â°L5178Y cells at a final concentration of 1-2 X 10" cells/ml were incubated in tissue culture medium with spleen cells for 30 min at 37Â°C;the suspension was then diluted and an inoculum containing 10s L5178Y cells injected into each mouse.
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Although they can be grown from 1 cell in general, they are han dled at a concentration of about 5 X IO4cells/ml; for nutritional reasons logarithmic growth stops when the culture exceeds IO6 lymphoma cells/ml. In the initial experiments some IO8immune spleen cells were added to 10 ml of a suspension of lymphoma cells at a concentration of 5 X IO4cells/ml (i.e., a ratio of 200:1), but under these conditions no significant effect could be observed on the rate of growth of the lymphoma. In the presence of comple ment (i.e., 2% guinea pig serum) immune lymphocytes stopped the growth of the lymphoma. These experiments were compli-
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cated by the fact that contact with complement for more than a few hours is toxic (probably because of its asparaginase activity) and this made it necessary to replace the medium. A pronounced in vitro effect on growth was brought about if the lymphoma cells were incubated with immune lymphocytes at a high concentra tion (i.e., 1 ml contained 10e L5178Y cells and 2 X 10" spleen cells) for 30 min at 37Â°C. After this treatment no adhesion of spleen cells to lymphoma cells could be observed, nor had the latter suffered any obvious morphologic changes which could be observed microscopically. The effect of the 30 min of contact with 
" The figures quoted were derived as follows:
No. of L5178Y cells in experimental culture 3-5 days after beginning of experiment
No. of cells in control culture 3-5 days after beginning of experiment X 100
The growth period varied in different experiments but in each case was the same for the experimental control cultures. This ratio will be equal to the number of cells surviving if the treatment does not produce a temporary inhibition of mitosis arid that L5178Y cells are either killed (i.e., prevented from dividing again) or grow normally. The control cultures contained normal DBA/2 spleen cells at a ratio of 200:1 but their effect on the rate of cell division was negligible. 6 An equal number of normal DBA/2 spleen cells was added to the immune spleen cells prior to in cubation with L5178Y cells.
c Bacillus of Calmette-GuÃ©rin. spleen cells at high concentration revealed itself as loss of ability of the cells to divide. Interference with growth is probably a more meaningful criteria for in vitro action than the morphologic cri teria that are usually used to assess cytotoxicity of antisera. Treatments such as irradiation and exposure to nitrogen mustard kill cells in the sense that they lose their capacity for indefinite reproduction; yet for a considerable time such cells would be classified as living by dye-uptake and morphologic tests. Contact with nonimmunc spleen cells does not retard at all the growth of the lymphoma cells in vitro, nor does their presence in the medium exert a deleterious effect; they would appear to metabolize too slowly to exhaust nutrients. Spleen cells from C57BL mice im munized 8 days previously by an i.p. injection of either 0.25 mg (wet weight) of bacillus Calmette-GuÃ©rin (B.C.G.) or 7 X IO6 spleen cells from AK mice with spontaneous leukemia also had no influence on the growth of the lymphoma in vitro (Table 8 ).
In the presence of immune spleen cells immunized against either L5178Y or DBA/2 spleen cells the number of lymphoma cells remains constant for about 2 days and then begins to in crease again at the normal rate. The lymphoma cells which have been affected by the immune lymphocytes do not divide but re main in situ and are counted until they break up and lyse. Some of the lymphoma cells retained their ability to divide indefinitely, and as these increase in number they become responsible for the outgrowth of the culture. By extrapolating the curves of the out growing cells backwards onto the axis showing cell number, the value of the fraction of cells that have "survived" treated can be obtained as described by Alexander and Mikulska (2, 3) . This figure is subject to a number of uncertainties (11) but is probably a valid measure for the relative cytotoxic effect of the different types of spleen cells and sera. The possibility can be envisaged that contact with the immune spleen cells does not remove the ability of the cell to divide indefinitely, but merely prevents cells from entering mitosis for 2 or 3 days after which the cells pro liferate normally. Such an explanation would be difficult to recon cile with the fact that the length of period for which the cell number remains stationary depends on the ratio of spleen cells used, or that in some instances no outgrowth occurs. On the cellkilling hypothesis the period of constant cell number is deter mined by the number of surviving cells, which must increase by division to more than 10*cells/ml to be observable in the pres ence of the 5 X IO4cells rendered incapable of division. Table 8 shows that the results obtained in vitro with spleen cells from L5178Y-immunized donors parallel very clearly those seen in vivo. Spleen cells from singly immunized donors are less effec tive than those from hyperimmunized donors, and the ratio at which all the cells are killed is in the range of 150-250 spleen cells/ L5178Y cell. In vitro as in vivo the spleen cells lose their activity after disruption by freezing and thawing.
The essential difference of the in vitro system is the cytotoxic activity of donor lymphocytes from animals that have been hyperimmunized with DBA/2 spleen cells. Thus lymphocytes directed against the normal transplantation antigens are capable of killing L5178Y cells, but this action is prevented by the pres ence of an excess of normal DBA/2 spleen cells. The latter pre sumably "neutralize" the spleen cells directed against the DBA/2 antigens, and the lymphoma cells escape damage. But the action of lymphocytes from donors immunized with L5178Y was not significantly antagonized by the presence of DBA/2 spleen cells; presumably in this case there are immune cells present which are directed against the specific antigen of the tumor and these are not "neutralized" by normal DBA/2 cells. The fact that the addition of large numbers of normal DBA/2 cells to donor spleen cells immunized against L5178Y has no detectable effect on the latters' capacity to prevent the growth of the lymphoma in vitro suggests that the immune spleen cells are predominantly directed against the tumor-specific antigens. Why the donor mice should react preferentially against the tumor-specific antigen rather than against the transplantation antigen remains to be explained.
In tissue culture, as in vivo,serum is only effective after hyperimmunization with L5178Y. The serum from animals hyper immunized with DBA/2 spleen cells has no effect on the lym phoma cells in vitro, but from this experiment it would be premature to deduce that there is a basic difference between the normal transplantation antigen and the specific antigen of the tumor in respect of their ability to evoke circulating antibodies.
Discussion
The growth-inhibitory effect, directed against established syngeneic tumors of small size, by lymphocytes from allogeneic mice that have been immunized with the L5178Y lymphoma can be interpreted as an action predominantly directed against the specific antigen which is present in the lymphoma and absent from normal DBA/2 cells. This is indicated by the failure of allogeneic spleen cells immunized against either L5178Y or DBA/2 spleen cells to give rise to any detectable deleterious ef fect to normal cells in the tumor-bearing DBA/2 mice. However, it is possible that the L5178Y cells are inherently more susceptible than normal cells to lymphocytes directed against H2 barriers and the principal reasons for believing that the eradication of the tumor is not due only to an effect induced by the normal histocompatibility barrier between DBA/2 and donor mice are: (a) failure of normal DBA/2 cells when added to the immune cells to antagonize their action; and (b) failure of CBA spleen cells hyper immunized with normal DBA/2 cells to exert an antitumor effect in vivo although they do so in vitro.
The in vivoexperiments do not however exclude the possibility that the ineffectiveness of lymphocytes from animals exposed to normal DBA/2 cells is due to the fact that even after hyperimmunization these are much less antigenic than a single treatment with tumor cells. The in vitro experiments provide evidence against this view7since they demonstrated that lymphocytes from donors immunized with both normal DBA/2 spleen and with lymphoma cells are cytotoxic. However, there is in vitro a quali tative difference between lymphocytes from donors immunized with normal and tumor tissue; the antilymphoma action of those from animals immunized with normal DBA/2 cells was antag onized by the addition of normal DBA/2 cells (Table 8) , while the lymphocytes from animals immunized with the lymphoma was only slightly affected ( Table 8) .
The superiority for treatment in vwo of the lymphocytes from allogeneic donors immunized with tumor can be satisfactorily ex plained by the presence of cell-bound antigens that react selec tively with the tumor cells. When considering possible practical application to tumor therapy quantitative limitations must be borne in mind and this procedure could only be of value for elimi nating relatively small numbers of cells that have escaped eradi-cation by other methods. Moreover, the animal's immune system against homografts must be functioning normally ; otherwise the injected foreign lymphocytes may cause a graft versus host reac tionâ€"a problem that has not been encountered in these experi ments but is known to occur (27) if the animals are irradiated prior to treatment with foreign lymphocytes. The mechanism at the cellular level remains to be established and caution should be exercised in equating the in vivoand in vitro reaction. In vitro, an essential step seems to be intimate contact between L5178Y cells and immune lymphocytes, although the interaction does not lead to rapid lysis of either cell, and the possi bility that the added spleen cells release antibody has not been eliminated. In vivo the possibility cannot be excluded that the reaction is less direct and may involve the intermediary of a cir culating factor.
The experiments with antisera may throw some light on the controversy about the role of circulating antibodies in the homograft reaction. The results reported here show that both in vivo and in vitro antiserum can bring about the rejection of a tumor which differs only very slightly in antigenic makeup from the host in which it grows, but that an active serum is only obtained after hyperimmunization. Those workers (17) who observed that lym phocytes were solely responsible for skin graft rejection usually employed a single immunization, whereas Gorer (12) , who em phasized the role of circulating antibodies in tumor immunology, invariably hyperimmunized. The suggestion had been made that there was a fundamental difference in the mechanism of rejection of grafts of tumor and of normal skin. The present data suggest that the immunization procedure may be a critical factor; the conclusion that an active serum is found only in a homograft reaction after hyperimmunization is in agreement with the recent demonstration by Ballantyne and Stetson (6) of active serum in accelerated skin graft rejection after repeated immunization. Al though the participation under certain conditions of serum in homograft reaction seems to be firmly established, in the system studied in this paper lymphocytes appear to make the predomi nant contribution.
